Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Logistic regression analysis identified prior neurologic event (P = .046), nonelective surgery (P = .047), absence of coronary artery disease (P = .035), and preoperative angiotensin-converting enzyme inhibitor use (P = .029) to be associated with 30-day ipsilateral stroke risk, but contralateral ICA occlusion remained an independent predictor in that model (odds ratio, 2.29; P = .026).
|
31445827 |
2020 |
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5).
|
31370961 |
2019 |
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several small, short-term trials suggested benefit on albuminuria in subjects with diabetes; however, results were not definitive.Welty et al. showed that eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for 1 year slowed progression of early-stage albuminuria in subjects with diabetes with clinical coronary artery disease on an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker, the majority of whom had an albumin/creatinine ratio (ACR) < 30 μg/mg.
|
30684085 |
2019 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Secondary outcome was self-reported medication adherence to evidence-based medications for CHD (antiplatelets, statins, β-blockers, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers).
|
31649528 |
2019 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results indicated that ACE INDEL polymorphism is an important predictor of coronary artery disease in Turkish Cypriots.
|
30414419 |
2019 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Secondary prevention of CHD recommended in standard guidelines (antiplatelet plus beta-blocker plus lipid-lowering drug, with or without angiotensin-converting enzyme inhibitors, ACEI, or angiotensin receptor blockers, ARB) was evaluated in relation to sociodemographic data and the time since the coronary event.
|
31483010 |
2019 |
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
A higher prevalence of anemia in CHF due to coronary heart disease may be associated with wider use of angiotensin converting enzyme inhibitors and acetylsalicylic acid.
|
30697681 |
2019 |
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We identified indications for medication (statins, aspirin, ACE inhibitors, clopidogrel) recommended in UK National Institute for Clinical Excellence (NICE) guidance for CHD (high risk, stable angina, stable angina plus diabetes, unstable angina, and myocardial infarction) and measured the persistence of indicated medication (time from initiation to discontinuation) across quintiles of the Welsh Index of Multiple Deprivation, an area-based measure of socio-economic inequality, using Cox regression frailty models.
|
29522561 |
2018 |
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prior stroke/TIA and/or PAD patients were less likely to receive evidence-based medical therapies (dual antiplatelet therapy: stroke/TIA= 88.6%, PAD= 86.6%, stroke/TIA+PAD= 85.7%, none= 92.2%, p<0.001; β-blockers: stroke/TIA= 77.1%, PAD= 72.1%, stroke/TIA+PAD= 71.9%, none= 80.8%, p<0.001; angiotensin-converting enzyme inhibitors/angiotensin receptor blockers: stroke/TIA= 86.3%, PAD= 83.6%, stroke/TIA+PAD= 83.2%, none= 87.1%, p=0.030) and to undergo percutaneous revascularization (stroke/TIA= 52.8%, PAD= 45.6%, stroke/TIA+PAD= 43.7%, none= 67.9%, p<0.001), despite more extensive coronary artery disease (three-vessel disease: stroke/TIA= 29.1%, PAD= 38.3%, stroke/TIA+PAD= 38.3%, none= 20.2%, p<0.001).
|
28627932 |
2018 |
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Effect of ACE I/D Polymorphisms Alone and With Concomitant Risk Factors on Coronary Artery Disease.
|
27895197 |
2018 |
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
|
30225928 |
2018 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CHD was diagnosed among 114 residents (60.3%) but only 60.5% of them were treated with aspirin (ASA), 45.6% with beta-blockers (BBs), 60.5% with angiotensin-converting enzyme inhibitor (ACEI), and 24.6% with statins.
|
29402648 |
2018 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Apolipoprotein B and angiotensin-converting enzyme polymorphisms and aerobic interval training: randomized controlled trial in coronary artery disease patients.
|
29846435 |
2018 |
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These 11 therapies were for patients with heart failure (angiotensin-converting-enzyme inhibitors, angiotensin II receptor blockers, aldosterone receptor antagonists and digoxin), stable coronary artery disease (intensive statin therapy), asthma exacerbations (early inhaled corticosteroids in the emergency department and anticholinergics), chronic obstructive pulmonary disease (long-acting muscarinic antagonists and long-acting beta-2 adrenoceptor agonists) and schizophrenia (second-generation antipsychotics and depot/maintenance antipsychotics).
|
30045724 |
2018 |
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Advanced Strategies in the Diagnosis and Treatment of Patients with Coronary Artery Disease and Heart Failure: When Heart Failure Causes Ischemia and Angiotensin Converting Enzyme Inhibitor and Betablockers Helps in Diuresis.
|
29283057 |
2018 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Rates of secondary prevention medications were lower among CHD versus ACS (all p < 0.0001): antiplatelet 94.3% vs 98.0%, beta-blocker 72.0% vs 80.0%, lipid-lowering therapy 94.7 vs 97.5%, and angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers 69.4% vs 73.7%, respectively.
|
29934227 |
2018 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thus, our study suggests that genetic polymorphisms of angiotensin-converting enzyme insertion/deletion are associated with in-stent restenosis in coronary artery disease patients following coronary stenting.
|
28196432 |
2017 |
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensin II receptor blockers versus angiotensin-converting enzyme inhibitors in patients with stable coronary artery disease: Prevalence, correlates, and prognostic impact (from the CORONOR study).
|
27283338 |
2017 |
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, EPA and DHA supplementation should be considered as additional therapy to an angiotensin-converting enzyme-inhibitor or angiotensin-receptor blocker in subjects with type 2 diabetes mellitus and coronary artery disease.
|
28710178 |
2017 |
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Before hospital admission, 84% of patients had antiplatelet therapy compared with 96% at discharge (P = 0.0004); 73% had a statin, compared with 83% at discharge (P = 0.001); 64% had an ACE inhibitor or ARB, compared with 63% at the time of discharge (P = 1).The proportion of patients receiving best medical treatment at admission and discharge increased in case of coronary artery disease (P = 0.004).
|
27908822 |
2017 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The communal relation of MTHFR, MTR, ACE gene polymorphisms and hyperhomocysteinemia as conceivable risk of coronary artery disease.
|
28514598 |
2017 |
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The proportions of individuals with CHD who received antiplatelet medications (30.1%), beta-blockers (34.2%), angiotensin-converting enzyme inhibitors, or angiotensin-receptor blockers (36.0%), or statins (18.0%) were low; with even lower proportions among stroke patients (antiplatelets 24.3%, angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers 37.6%, statins 9.8%).
|
27773540 |
2017 |
Coronary heart disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
A total of 177 patients with coronary heart disease (CHD) complicated with hypertension was continuously enrolled in this study and randomly divided into traditional anti-hypertension group (group A: 130/80 mm Hg ≤ BP ≤ 140/90 mm Hg; anti-hypertensive drugs: β blockers and angiotensin converting enzyme inhibitor, n=84) and potent anti-hypertension group (group B: BP <130/80 mm Hg; dosage and frequency in group B > group A, n=93).
|
28745786 |
2017 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Relationship of the rs1799752 polymorphism of the angiotensin-converting enzyme gene and the rs699 polymorphism of the angiotensinogen gene to the process of in-stent restenosis in a population of Polish patients with stable coronary artery disease.
|
27162064 |
2016 |
Coronary heart disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association between angiotensin-converting-enzyme (ACE) gene polymorphisms and different clinical and echocardiographic outcomes has been described in patients with heart failure (HF) and coronary artery disease.
|
27812677 |
2016 |